US 12,351,638 B2
Chimeric antigen receptors targeting BCMA and methods of use thereof
Xiaohu Fan, Edmonton (CA); Qiuchuan Zhuang, Jiangsu (CN); Pingyan Wang, Anhui (CN); Lin Wang, Jiangsu (CN); Lei Yang, Anhui (CN); Jiaying Hao, Jiangsu (CN); Dan Zhao, Jiangsu (CN); and Xian He, Jiangsu (CN)
Assigned to LEGEND BIOTECH USA INC., Wilmington, DE (US)
Filed by Legend Biotech USA Inc., Wilmington, DE (US)
Filed on Nov. 3, 2021, as Appl. No. 17/518,123.
Application 17/518,123 is a division of application No. 17/168,100, filed on Feb. 4, 2021, granted, now 11,186,647, issued on Nov. 30, 2021.
Application 17/168,100 is a continuation of application No. 16/303,587, granted, now 11,535,677, previously published as PCT/CN2017/096938, filed on Aug. 10, 2017.
Claims priority of application No. PCT/CN2016/094408 (WO), filed on Aug. 10, 2016.
Prior Publication US 2022/0127371 A1, Apr. 28, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); C07K 19/00 (2006.01); C12N 5/0783 (2010.01); C12N 5/10 (2006.01); C12N 15/62 (2006.01); C12N 15/63 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); A61K 40/4215 (2025.01); A61K 40/4221 (2025.01); A61K 40/4222 (2025.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70575 (2013.01); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); C07K 16/2803 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); C07K 16/3061 (2013.01); C07K 19/00 (2013.01); C12N 5/0636 (2013.01); C12N 5/10 (2013.01); C12N 15/62 (2013.01); C12N 15/63 (2013.01); A61K 2239/29 (2023.05); A61K 2239/48 (2023.05); C07K 2317/22 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/21 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2510/00 (2013.01)] 8 Claims
 
1. An isolated nucleic acid comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR) comprising a polypeptide comprising,
(a) an extracellular antigen binding domain comprising a first anti-BCMA single domain antibody (sdAb), and a second anti-BCMA sdAb; and wherein each of the first and second sdAb is a VHH domain;
(b) a transmembrane domain; and
(c) an intracellular signaling domain,
wherein:
(i) the first anti-BCMA sdAb comprises a CDR1, a CDR2 and a CDR3 as set forth in the VHH domain comprising the amino acid sequence of SEQ ID NO: 124, and
(ii) the second anti-BCMA sdAb comprises a CDR1, a CDR2, and a CDR3 as set forth in the VHH domain comprising the amino acid sequence of SEQ ID NO: 117.